George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLife Settlemen Regulatory News (LSAA)

Share Price Information for Life Settlemen (LSAA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.70
Bid: 1.60
Ask: 1.80
Change: 0.00 (0.00%)
Spread: 0.20 (12.50%)
Open: 1.70
High: 1.70
Low: 1.70
Prev. Close: 1.70
LSAA Live PriceLast checked at -
Life Settlement Assets A is an Investment Trust

To generate long-term returns for investors by investing in the life settlement market.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

28 Apr 2023 07:00

RNS Number : 7833X
Life Settlement Assets PLC
28 April 2023
 

Life Settlement Assets PLC

(the "Company" or "LSA")

 

Results for the year ended 31 December 2022

 

 

LSA, a closed-ended investment trust company which invests in, and manages, portfolios of whole and fractional interests in life settlement policies issued by life insurance companies operating predominantly in the United States, is pleased to announce its results for the year ended 31 December 2022, and the publication of its 2022 Annual Report.

 

The highlights of the year were as follows:

 

Finalisation of MBC litigation

· Formal acceptance on 2 March 2023 by the US Court of the southern District of Florida, Miami Division, of the sale of life policies portfolio to Acheron Portfolio Trust ("APT"), on behalf of the Company.

· Mitigation of operational risk with fractional interests in policies now able to be consolidated into policies 100% owned by APT.

· More cost-effective operations in the future with a significant reduction in future legal costs.

· Reduced need to retain cash following the life policies portfolio purchase, together with a resumption of dividends payable by the Company.

Net Asset Value

· USD 109.9 million, representing an uplift of USD 0.6 million during the year.

 

Maturities

· Maturities totalling USD 27.2 million were declared - of these, USD 20.9 million were non-HIV policies, and USD 6.3 million were HIV policies.

 

Costs

· Decrease in total ongoing charges ratio from 7.6% to 7.1% of NAV in 2022.

· Decrease in ongoing charges ratio excluding policy servicing fees and legal costs from 3.6% to 3.0% of NAV.

· The Company has agreed a reduction of the Investment Manager performance fee from 20% to 10% of the total distributions made by the Company over the agreed hurdle rate.

 

Dividend

· Since the year end, following the initial indication of the ruling of the US Court, LSA announced on 2 February 2023, the declaration of a special dividend of 6.0209 cents per share totalling approximately USD 3.0 million, which was paid to Shareholders on 24 February 2023.

 

Michael Baines, Chairman, commented:

"The successful conclusion of your Company's long running litigation against MBC marks a significant development in our strategy of unlocking value for Shareholders. It removes an important area of risk, builds value, and unlocks alternatives for the deployment of funds arising on the maturity of policies. It also means that the Board's attention can focus solely on the broader risk issues in the portfolio, including that of HIV mortality.

 

The Board is acutely aware of the impact that last year's cash retention policy has had on the level of discount at which LSA's shares trade. Therefore, in addition to the announcement of a special dividend and a return to the previous approach to dividend payments generally, the Board is actively considering further options to reduce this discount, which will be communicated to Shareholders at the appropriate time.

 

Given that the non-HIV portfolio is now expected to mature faster than the HIV portfolio, we will continue to closely monitor research on mortality in general to guide future decisions. The past track record of assessing risk across the portfolio gives the Board confidence that outcomes should be achieved which will continue to underpin the value proposition for Shareholders."

 

The Directors are pleased to attach the Company's annual report and financial statements for the year ended 31 December 2022.

 

Click on the following link, or paste it into your web browser, to view the associated PDF document:

http://www.rns-pdf.londonstockexchange.com/rns/7833X_1-2023-4-27.pdf

The annual report and financial statements for the year ended 31 December 2022 may also be downloaded from the Company's website at

 https://www.lsaplc.com/investor-relations/company-reports/published-reports/

 

For further information contact:

 

Acheron Capital Limited (Investment Manager)

Jean-Michel Paul

020 7258 5990

 

Shore Capital (Financial Adviser and Broker)

Robert Finlay

020 7408 4090

 

ISCA Administration Services Limited

Company Secretary

Tel: 01392 487056

 

DISCLAIMER

Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

 

NATIONAL STORAGE MECHANISM

A copy of the 2022 Annual Report and Accounts will be submitted shortly to the National Storage Mechanism ("NSM") and will be available for inspection at the NSM, which is situated at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

Notes to Editors

Life Settlement Assets PLC is a closed-ended investment trust company which invests in, and manages, portfolios of whole and fractional interests in life settlement policies issued by life insurance companies operating predominantly in the United States. The Company seeks to generate long-term returns for investors by investing in the life settlement market, through each of the separate Share Classes. The Company aims to manage its investment in portfolios of life settlement products so that the realised value of the policy maturities exceeds the aggregate cost of acquiring the policies, ongoing premiums, management fees and other operational costs.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR PPUGGCUPWGBM
Date   Source Headline
1st Mar 20244:13 pmRNSPolicy Maturities
1st Mar 20243:40 pmRNSNet Asset Value(s)
15th Feb 20243:00 pmRNSDividend Declaration
2nd Feb 20244:15 pmRNSNet Asset Value(s)
24th Jan 20249:54 amRNSNet Asset Value(s)
20th Dec 20237:00 amRNSPolicy Maturities and update on MBC settlement
13th Dec 202310:35 amRNSHolding(s) in Company
13th Nov 20239:34 amRNSNet Asset Value(s)
17th Oct 20235:14 pmRNSNet Asset Value(s)
27th Sep 20237:00 amRNSHalf-year Report
20th Sep 202311:53 amRNSNet Asset Value(s)
18th Aug 20239:52 amRNSNet Asset Value(s)
17th Jul 20231:06 pmRNSNet Asset Value(s)
14th Jun 20234:14 pmRNSAGM Statement
2nd Jun 202310:17 amRNSNet Asset Value(s)
30th May 202312:33 pmRNSNet Asset Value(s)
16th May 202312:26 pmRNSNet Asset Value(s)
28th Apr 20237:00 amRNSFinal Results
5th Apr 20239:33 amRNSNet Asset Value(s)
5th Apr 20237:00 amRNSUpdate on MBC Auction
6th Mar 20233:22 pmRNSHolding(s) in Company
6th Mar 20237:00 amRNSUpdate on MBC Auction
23rd Feb 20233:25 pmRNSNet Asset Value(s)
23rd Feb 20231:56 pmRNSHolding(s) in Company
2nd Feb 20237:00 amRNSDividend Declaration
27th Jan 20234:44 pmRNSUpdate on MBC Auction
16th Jan 202311:40 amRNSNet Asset Value(s)
30th Dec 20227:00 amRNSUpdate on MBC Auction
12th Dec 20227:00 amRNSUpdate on MBC Auction
5th Dec 20222:40 pmRNSStatement re MBC Auction
2nd Dec 20226:21 pmRNSNet Asset Value(s)
14th Nov 202211:24 amRNSNet Asset Value(s)
29th Sep 20223:42 pmRNSNet Asset Value(s)
28th Sep 20227:00 amRNSHalf-year Report
8th Sep 20221:32 pmRNSNet Asset Value(s)
10th Aug 202210:09 amRNSNet Asset Value(s)
12th Jul 20225:35 pmRNSHolding(s) in Company
7th Jul 202212:07 pmRNSNet Asset Value(s)
30th Jun 20227:00 amRNSStatement re agreement to reduce performance fee
23rd Jun 20224:22 pmRNSResult of Annual General Meeting
22nd Jun 20224:56 pmRNSNet Asset Value(s)
26th May 202210:56 amRNSNet Asset Value(s)
23rd May 20222:16 pmRNSNet Asset Value(s)
22nd Apr 20227:00 amRNSFinal Results
30th Mar 202210:03 amRNSNet Asset Value(s)
2nd Mar 202211:22 amRNSNet Asset Value(s)
16th Feb 20224:41 pmRNSHolding(s) in Company
19th Jan 20221:05 pmRNSNet Asset Value(s)
21st Dec 202112:08 pmRNSHolding(s) in Company
15th Dec 202110:07 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.